(Q33912099)

30 July 2017

title

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering (English)

1 reference

30 July 2017

0 references

1 reference

Kjekshus J

1 reference

30 July 2017

Pedersen TR

1 reference

30 July 2017

Wilhelmsen L

1 reference

30 July 2017

Faergeman O

1 reference

30 July 2017

Strandberg TE

1 reference

30 July 2017

Thorgeirsson G

1 reference

30 July 2017

Troedsson L

1 reference

30 July 2017

Kristianson J

1 reference

30 July 2017

Berg K

1 reference

30 July 2017

Cook TJ

1 reference

30 July 2017

Haghfelt T

1 reference

30 July 2017

Miettinen T

1 reference

30 July 2017

Olsson AG

1 reference

30 July 2017

Pyörälä K

1 reference

30 July 2017

Wedel H

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

American Journal of Cardiology

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

257-262

1 reference

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Cholesterol reduction yields clinical benefit: impact of statin trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Carcinogenicity of lipid-lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

The Helsinki Heart Study: an 8.5-year safety and mortality follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900910-3

10.1016/S0002-9149(00)00910-3

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference